** Jefferies says Fisher & Paykel Healthcare Corp's FPH.NZ combination of product innovation, promotion of clinical change and continuous operational improvement continues to deliver, following its annual results
** Brokerage upgrades stock to "buy" from "hold", hikes price target to NZ$40.9 from NZ$39.4
** Medical equipment maker on Wednesday reported FY25 net income of NZ$377.2 million ($224.70 million), beating its forecast of NZ$320 million to NZ$370 million
** Jefferies says FPH successfully converted clinical change into product sales through fiscal 2025, even with a moderate flu season
** Brokerage also believes limited tariff impacts and FPH's practice of continuous process improvement should lead to increased operating leverage
** Two of 12 analysts rate the stock "buy" or higher, eight "hold" and two "sell" or lower; their median PT is NZ$37, according to data compiled by LSEG
** Stock down 8.9% YTD, as of last close
($1 = 1.6787 New Zealand dollars)
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.